EUVIMEDEUVIMED entdecken
EditorialKommentar

Editorial comment on “Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain”

Ayobami Akenroye iD, Wanda Phipatanakul

Pediatric Allergy and Immunology · 2023

DOI: 10.1111/pai.13980 ↗

Kurz gefasst

Editorial in der Zeitschrift Pediatric Allergy and Immunology, 2023. Verfasst von Ayobami Akenroye und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Brigham & Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, US…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Hypersensitivity. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsHypersensitivityHumansChildOmalizumabCost-Benefit AnalysisSpainTreatment Outcome

Substanzen

OmalizumabAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Brigham & Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Channing Division of Network Medicine, Brigham & Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Ayobami Akenroye

Zitieren

APA

Akenroye, A., & Phipatanakul, W. (2023). Editorial comment on “Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain”. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13980

Vancouver

Akenroye A, Phipatanakul W. Editorial comment on “Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain”. Pediatric Allergy and Immunology. 2023. doi:10.1111/pai.13980

BibTeX
@article{Akenroye2023,
  author = {Akenroye, Ayobami and Phipatanakul, Wanda},
  title = {Editorial comment on “Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain”},
  journal = {Pediatric Allergy and Immunology},
  year = {2023},
  doi = {10.1111/pai.13980}
}
Kostenlos starten →